June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Corneal Transplant in patients with uveitis and Fuchs Endothelial Dystrophy CASE Series
Author Affiliations & Notes
  • Diana Morvey
    Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, United States
  • Andrew Philip
    Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, United States
  • Stephen Anesi
    Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Diana Morvey None; Andrew Philip None; Stephen Anesi None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 632. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Diana Morvey, Andrew Philip, Stephen Anesi; Corneal Transplant in patients with uveitis and Fuchs Endothelial Dystrophy CASE Series. Invest. Ophthalmol. Vis. Sci. 2023;64(8):632.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Fuchs’ endothelial dystrophy (FED) is a degenerative condition of the corneal endothelium, leading to loss of corneal endothelial cells, potentially causing corneal haze and decreased vision. Various methods of corneal transplant may be performed to improve vision. Uveitis leads to anterior chamber pathology that may make surgeries, such as corneal transplants, more challenging and lead to worse outcomes or prognosis. We aimed to describe outcomes in patients with uveitis and FED after either Descemet membrane endothelial keratoplasty (DMEK), Descemet stripping endothelial keratoplasty (DSEK), or penetrating keratoplasty (PK).

Methods : This was a retrospective single-center study looking at uveitis patients who had keratoplasty from 2009 to 2022 at the Massachusetts Eye Research and Surgery Institution (MERSI), in Waltham, MA. All surgeries were performed by a single surgeon (S.A.). We defined success as stability or improvement in visual acuity after surgery without the need for regraft or other corneal transplantation for at least one year.

Results : Ten eyes in 7 patients were included, with 18 procedures documented including 8 DSEK, 2 DMEK, and 8 PK. Of the 8 DSEK, there were 6 (75%) successes and 2 (25%) failures. Of the 2 DMEKs performed, one (50%) was a success and one (50%) was a failure. For the 8 PKs there were 7 (87.5%) successes and 1 (12.5%) failure.
Of the 8 DSEK, 5 (62.5%) were primary procedures and 3 (37.5%) were performed after either DMEK or PK. Of 5 primary DSEAK, 3 eventually required PK. Of 8 PKs, 2 were primary and 6 repeat procedures. One patient had repeat PK 3 times over 10 years, and then eventually DSEK. The remaining 3 cases of non-primary PK were performed after DSEK.

Conclusions : In this study, PK was the most successful procedure, followed by DSEK and then DMEK. While successful, cases with uveitis and FED may be at an increased risk of repeat corneal transplantation.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×